Back

Epidemiology and Nomogram Development for Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL-NOS): Insights from the SEER Database

Wang, F.

2023-10-02 hematology
10.1101/2023.09.29.23296356 medRxiv
Show abstract

BackgroundChronic Eosinophilic Leukemia, Not Otherwise Specified (CEL-NOS), a rare and intricate hematological disorder characterized by uncontrolled eosinophilic proliferation, presents clinical challenges owing to its infrequency. This study aimed to investigate the epidemiology and develop a prognostic nomogram for CEL-NOS patients. MethodsUtilizing the Surveillance, Epidemiology and End Results (SEER) database, CEL-NOS cases diagnosed between 2001 and 2020 were analyzed for incidence rates, clinical profiles, and survival outcomes. Patients were randomly divided into training and validation cohorts (7:3 ratio). LASSO regression analysis and Cox regression analysis were performed to screen the prognostic factors for overall survival. A nomogram was then constructed and validated to predict the 3- and 5-year overall survival probability of CEL-NOS patients by incorporating these factors. ResultsThe incidence rate of CEL-NOS was very low, with an average of 0.033 per 100,000 person-years from 2001 to 2020. The incidence rate significantly increased with age and was higher in males than females. The mean age at diagnosis was 57 years. Prognostic analysis identified advanced age, specific marital statuses, and secondary CEL-NOS as independent and adverse predictors of overall survival (OS). To facilitate personalized prognostication, a nomogram was developed incorporating these factors, demonstrating good calibration and discrimination. Risk stratification using the nomogram effectively differentiated patients into low- and high-risk groups. ConclusionsThis study enhances our understanding of CEL-NOS, offering novel insights into its epidemiology, demographics, and prognostic determinants, while providing a possible prognostication tool for clinical use. However, further research is warranted to elucidate molecular mechanisms and optimize therapeutic strategies for CEL-NOS.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
British Journal of Haematology
15 papers in training set
Top 0.1%
19.3%
2
Blood Cancer Journal
11 papers in training set
Top 0.1%
8.7%
3
Blood Advances
54 papers in training set
Top 0.2%
7.4%
4
Leukemia
39 papers in training set
Top 0.2%
7.0%
5
PLOS ONE
4510 papers in training set
Top 26%
6.6%
6
Transplantation
13 papers in training set
Top 0.1%
3.8%
50% of probability mass above
7
Clinical Chemistry and Laboratory Medicine (CCLM)
12 papers in training set
Top 0.1%
3.2%
8
Blood
67 papers in training set
Top 0.5%
3.0%
9
Cytometry Part A
30 papers in training set
Top 0.1%
3.0%
10
Frontiers in Immunology
586 papers in training set
Top 3%
2.1%
11
Molecular Oncology
50 papers in training set
Top 0.3%
1.9%
12
Medicine
30 papers in training set
Top 0.9%
1.9%
13
npj Precision Oncology
48 papers in training set
Top 0.5%
1.7%
14
Journal of Leukocyte Biology
40 papers in training set
Top 0.2%
1.7%
15
Annals of Translational Medicine
17 papers in training set
Top 0.6%
1.7%
16
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.4%
1.5%
17
Scientific Reports
3102 papers in training set
Top 61%
1.5%
18
Heliyon
146 papers in training set
Top 3%
1.3%
19
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 2%
1.3%
20
Modern Pathology
21 papers in training set
Top 0.3%
1.3%
21
Molecular Biology Reports
19 papers in training set
Top 0.3%
1.3%
22
Frontiers in Medicine
113 papers in training set
Top 5%
1.0%
23
Vaccines
196 papers in training set
Top 2%
0.9%
24
Biomedicines
66 papers in training set
Top 2%
0.9%
25
BMC Public Health
147 papers in training set
Top 5%
0.8%
26
Archives of Clinical and Biomedical Research
28 papers in training set
Top 2%
0.8%
27
Haematologica
24 papers in training set
Top 0.6%
0.5%
28
European Journal of Neurology
20 papers in training set
Top 0.9%
0.5%
29
Cancers
200 papers in training set
Top 5%
0.5%